Suvorexant Drug Asset Due Diligence Report 2026

This Suvorexant Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

100

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Suvorexant can convert its Small molecule drug profile and OX1R x OX2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Suvorexant (query alias: suvorexant)
Modality / target	Small molecule drug; OX1R x OX2R; OX1R antagonists, OX2R antagonists
Highest global status	Approved
Originator	Merck Sharp & Dohme Corp.
Active developers	Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC, Merck Sharp & Dohme (Australia) Pty Ltd.

The MCP disease footprint includes Sleep Initiation and Maintenance Disorders, Delirium, Alzheimer Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07686731	Phase 4	Not yet recruiting	142	Change from Baseline in PTSD Symptom Severity as Assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 4, Week 8, and 6 Months
NCT07214207	Phase 2	Recruiting	250	Proportion of Heavy Drinking Days
NCT06854224	Phase 2	Recruiting	30	Implicit Association Tests (IATs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial

Phase 4; n=100; evaluation: Negative. Reported fields: WASO(nighttime) = 184.2 minutes ( 80.4 - 304.2); WASO(nighttime) = 200.7 minutes ( 112.1 - 328.4)

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

Phase 4; n=31; evaluation: not stated. Reported fields: ISI at Baseline(Mean) = 14.5 units on a scale (Standard Deviation, 4.2); -; ISI at Baseline(Mean) = 14.6 units on a scale (Standard Deviation, 3.9)

Suvorexant for alcohol use disorder and post-traumatic stress disorder: study protocol for a phase II randomized clinical trial

Phase 2; n=98; evaluation: Positive. Reported fields: AE = The most common adverse events (≥5%) reported by participants treated with suvorexant were next-day re- ported sedation (29.7%), headache (17.2%), and nausea (5.4%).

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Suvorexant addresses Sleep Initiation and Maintenance Disorders, Delirium, Alzheimer Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 16 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: OX1R x OX2R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-03-11	Idorsia and Pharmalink sign agreement to distribute Quviviq	Approved	Financial terms not disclosed
2026-01-28	Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America	Approved	US$20.0M milestones
2025-07-11	Eolas Therapeutics Secures Full Development Rights to AZD4041	Preclinical	US$145.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Preparation method of suvorexant”. The milestone feed surfaced a patent-application signal described as “Novel process for the preparation of suvorexant”. The milestone feed surfaced a patent-application signal described as “Preparation method of suvorexant”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO